Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. - Wikidata - wikimedia - TriplyDB

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

http://www.wikidata.org/entity/Q34205630

about

Interlaboratory comparison of three multiplexed bead-based immunoassays for measuring serum antibodies to pneumococcal polysaccharides Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease?Salivary antibodies induced by the seven-valent PncOMPC conjugate vaccine in the Finnish Otitis Media Vaccine Trial.Nonencapsulated Streptococcus pneumoniae: Emergence and Pathogenesis Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children Comparison of diagnostic criteria for common variable immunodeficiency disorder Development and characterization of a multiplex bead-based immunoassay to quantify pneumococcal capsular polysaccharide-specific antibodies Multilaboratory assessment of threshold versus fold-change algorithms for minimizing analytical variability in multiplexed pneumococcal IgG measurements Comparison of a new multiplex binding assay versus the enzyme-linked immunosorbent assay for measurement of serotype-specific pneumococcal capsular polysaccharide IgG Efficacy of pneumococcal immunization in patients with renal disease--what is the data?Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection.Serotype 6B from a pneumococcal polysaccharide vaccine induces cross-functional antibody responses in adults to serotypes 6A, 6C, and 6D.Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines Outpatient antibiotic prescribing in the United States: 2000 to 2010.Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine.Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants.Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines.Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera.Antibody response to a T-cell-independent antigen is preserved after splenic artery embolization for trauma.Evaluation of multiplex flow cytometric opsonophagocytic assays for determination of functional anticapsular antibodies to Streptococcus pneumoniae Type-specific antibodies to pneumococcal capsular polysaccharide acquired either naturally or after vaccination with Prevenar in children with underlying chronic or recurrent lung diseases.Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines.Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children.Serum antibody responses to pneumococcal colonization in the first 2 years of life: results from an SE Asian longitudinal cohort study Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia.Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection.Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization.Seroprevalence of Antibody-Mediated, Complement-Dependent Opsonophagocytic Activity against Neisseria meningitidis Serogroup B in England.Conjugate vaccines.RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies.Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.

P2860

Q23918185-DA423220-E6B1-4C58-9A1D-048D9B3AA7DC Q24245934-1821D66C-4A6F-422C-BC8D-5BDB23983156 Q24809188-BAC3ECC7-8738-4916-8FB9-77AC625B8D83 Q24812739-E70802DB-91F9-4011-B790-07DC84F01A41 Q26752517-996CC28A-8B54-4E96-84D1-B718B0A25C67 Q26782280-A95401CF-2DBD-47C8-8803-C13DDFAAB468 Q26859119-68E0DCD1-4A2C-466F-A45A-637BB5F24C07 Q28387340-5FBE3074-2F0F-4015-999A-B47AF2624FE1 Q28390191-5F790219-C8FA-409C-A826-85C601365321 Q28392402-8900C6F5-5C2E-4E01-81EE-0CDDAC34CA78 Q30947054-D5428B9C-F731-47C3-9994-313D510B8B02 Q33557154-CD8B1BD3-56DC-4395-8F0C-0CE3438DE6F9 Q33593722-C1F6205F-42ED-44B1-BA4E-2874135CAB4D Q33593822-F0B224CB-F981-446C-834D-B30F3D12E9B4 Q33595352-8268D93F-D3D9-41C6-9A99-6C7A03422C23 Q33613509-443CEE55-F2C8-4D81-BE02-E03609AA6216 Q33790880-2FF45000-CDD7-4667-84B7-0CA5822D9B3A Q33916408-49B9B8CD-8C62-4D03-8277-8CD87DAE5C0A Q34072420-770C5262-B602-4350-A2FD-D5FDAEB10423 Q34175136-00847BEA-49D3-499E-80FF-B4467A35DD88 Q34429349-15DE4766-C195-42F3-8A68-BF3BCCC38DE7 Q34444503-8B7EF805-66A1-4948-9520-3B5661157763 Q34484048-905F2F8C-17C8-40F6-BE22-9E581EA1C033 Q34593024-B8B7E1A3-3D13-4BA8-A2DA-68CA0B44F12A Q34601410-9EE13A0C-DFE1-4F5C-97CD-3FC0EB4B30B0 Q34720274-589684A8-9AD1-4D3A-9304-45E67E33C7A5 Q34738780-58F19D6B-56EB-4692-8D4F-A505AF063988 Q34796940-5AB0264C-E3AD-4041-B0D9-3E390EFBC33A Q34803614-49F52C40-3CB3-4BA2-A51F-51995846EF4E Q34981631-C00B5094-D7BE-4E80-AF08-E7E3ACBC49F7 Q35042732-6ACD03ED-3D10-4308-81D1-01B227802EA8 Q35134469-508DE583-54A0-4B1E-AAF6-38B778720B5C Q35139987-963A20BC-1F0F-4120-852D-86BD0D38E964 Q35194417-F4C84307-91DA-4644-9E8E-CA5B0C514EB3 Q35199219-B2202248-BCAE-4473-B452-1D7081F22386 Q35548013-BAF50C3F-7712-4C92-9512-F3C4D1F0D82B Q35623292-CC5D75FB-CF52-4F18-B67A-33D97785E50E Q35665417-9ECC7260-9371-441D-B7AB-7DE1FE25A5F1 Q35783918-693C9150-26E6-4485-A9C3-BD85818CA061 Q35874108-FD723F8C-E7B7-4AD4-84AA-A52C9F86D056

P2860

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

http://www.wikidata.org/entity/Q34205630

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Serological criteria for evalu ...... rmulations for use in infants.

@ast

Serological criteria for evalu ...... rmulations for use in infants.

@en

Serological criteria for evalu ...... rmulations for use in infants.

@nl

type

label

Serological criteria for evalu ...... rmulations for use in infants.

@ast

Serological criteria for evalu ...... rmulations for use in infants.

@en

Serological criteria for evalu ...... rmulations for use in infants.

@nl

prefLabel

Serological criteria for evalu ...... rmulations for use in infants.

@ast

Serological criteria for evalu ...... rmulations for use in infants.

@en

Serological criteria for evalu ...... rmulations for use in infants.

@nl

P1433

Q34205630-2BE90F7E-7834-4987-9B2F-76AFE5A9372F

P1476

Q34205630-3F0C45BC-E26C-4CE4-92D0-F5F14ED7718E

P2093

Q34205630-20E654B3-C330-4F08-880B-D1F5B1A7006E

Q34205630-2DE82EF7-4DE8-4175-BE4A-41C43B96EE81

Q34205630-5766A803-8165-4F3F-9FF1-2CEC6F2868E4

Q34205630-82444018-8ACE-49DF-9C11-0FFE0D38E26C

Q34205630-88D4B7A3-2BF5-43E8-B50E-04F8325DDB64

Q34205630-A019683B-DD85-4B03-AA39-E1F85841683F

Q34205630-ABABA30E-E934-4CC1-BD75-4AD585BE02E4

Q34205630-BDFE2474-C292-437C-8206-2E8B3615228A

Q34205630-DE96D186-3417-42C3-A4FE-1C684B6AEC28

Q34205630-E0AA9556-707F-4472-B37E-11BD94BEF238

P304

Q34205630-9EE352D8-DA08-48C4-8A5A-22CAEA1B45D8

P31

Q34205630-12B96DA4-60CA-4655-8308-67C3F2FE8086

P356

Q34205630-1B7C3D4D-114D-4D31-B403-27CAD6E2E527

P407

Q34205630-5DA4479F-57C3-4704-B865-F0115DE66E3C

P433

Q34205630-2A8914A5-DB7C-455F-9102-77BDB8908937

P478

Q34205630-3CBB7FF7-5D4A-47E0-B0E4-EF446674807D

P50

Q34205630-43BBB3AD-57EE-436F-856F-7893934B8949

Q34205630-7EE5D036-A936-4387-A7B3-884822DDDDF4

P577

Q34205630-E40A4955-13E9-4ACA-BAD3-17741796BB35

P698

Q34205630-8DE2814A-D975-48BF-A8D6-927F5531FA67

P356

S0264-410X(03)00230-5

P1433

P1476

Serological criteria for evalu ...... rmulations for use in infants.

@en

P2093

Brian Plikaytis

http://www.w3.org/2001/XMLSchema#string

George Carlone

http://www.w3.org/2001/XMLSchema#string

George Siber

http://www.w3.org/2001/XMLSchema#string

Helena Käyhty

http://www.w3.org/2001/XMLSchema#string

Ih Chang

http://www.w3.org/2001/XMLSchema#string

Jay Butler

http://www.w3.org/2001/XMLSchema#string

Luis Jódar

http://www.w3.org/2001/XMLSchema#string

Robert Kohberger

http://www.w3.org/2001/XMLSchema#string

Ron Dagan

http://www.w3.org/2001/XMLSchema#string

Thomas Cherian

http://www.w3.org/2001/XMLSchema#string

P304

3265-3272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0264-410X(03)00230-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

David Goldblatt

Keith P. Klugman

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12804857

http://www.w3.org/2001/XMLSchema#string